Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells

McDonald, Elizabeth S.; Mankoff, Julia; Makvandi, Mehran; Chu, Wenhua; Chu, Yunxiang; Mach, Robert H.; Zeng, Chenbo

doi:10.1016/j.bbrc.2017.03.122

Title: Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells

Full Record
Other Related Research

Authors:: McDonald, Elizabeth S.; Mankoff, Julia; Makvandi, Mehran; Chu, Wenhua; Chu, Yunxiang; Mach, Robert H.; Zeng, Chenbo

Publication Date:: Mon May 01 00:00:00 EDT 2017

Sponsoring Org.:: USDOE

OSTI Identifier:: 1396512

Grant/Contract Number:: SE0012476

Resource Type:: Publisher's Accepted Manuscript

Journal Name:: Biochemical and Biophysical Research Communications

Additional Journal Information:: Journal Name: Biochemical and Biophysical Research Communications Journal Volume: 486 Journal Issue: 3; Journal ID: ISSN 0006-291X

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Citation Formats


                    McDonald, Elizabeth S., Mankoff, Julia, Makvandi, Mehran, Chu, Wenhua, Chu, Yunxiang, Mach, Robert H., and Zeng, Chenbo. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.  United States: N. p., 2017. 
Web.  doi:10.1016/j.bbrc.2017.03.122.

Copy to clipboard


                    McDonald, Elizabeth S., Mankoff, Julia, Makvandi, Mehran, Chu, Wenhua, Chu, Yunxiang, Mach, Robert H., & Zeng, Chenbo. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.  United States.  https://doi.org/10.1016/j.bbrc.2017.03.122

Copy to clipboard


                    McDonald, Elizabeth S., Mankoff, Julia, Makvandi, Mehran, Chu, Wenhua, Chu, Yunxiang, Mach, Robert H., and Zeng, Chenbo. Mon .  
"Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells".  United States.  https://doi.org/10.1016/j.bbrc.2017.03.122.

Copy to clipboard


                    
@article{osti_1396512,

  title        = {Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells},

  author       = {McDonald, Elizabeth S. and Mankoff, Julia and Makvandi, Mehran and Chu, Wenhua and Chu, Yunxiang and Mach, Robert H. and Zeng, Chenbo},

  abstractNote = {},

  doi          = {10.1016/j.bbrc.2017.03.122},

  journal      = {Biochemical and Biophysical Research Communications},

  number       = 3,

  volume       = 486,

  place        = {United States},

  year         = {Mon May 01 00:00:00 EDT 2017},

  month        = {Mon May 01 00:00:00 EDT 2017}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (Publisher)

Publisher's Version of Record
https://doi.org/10.1016/j.bbrc.2017.03.122

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 8 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells

Journal Article McDonald, Elizabeth S. ; Mankoff, Julia ; Makvandi, Mehran ; ... - Biochemical and Biophysical Research Communications

The sigma-2 receptor is overexpressed in proliferating cells compared to quiescent cells and has been used as a target for imaging solid tumors by positron emission tomography. Recent work has suggested that the sigma-2 receptor may also be an effective therapeutic target for cancer therapy. Poly (ADP-ribose) polymerase (PARP) is a family of enzymes involved in DNA damage response. In this study, we looked for potential synergy of cytotoxicity between PARP inhibitors and sigma-2 receptor ligands in breast cancer cell lines. We showed that the PARP inhibitor, YUN3-6, sensitized mouse breast cancer cell line, EMT6, to sigma-2 receptor ligand (SV119,more »« less
https://doi.org/10.1016/J.BBRC.2017.03.122
Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer

Journal Article Wang, Lingfei ; Yu, Xiaojie ; Dong, Jian ; ... - Biochemical and Biophysical Research Communications

Despite of the effectiveness of the anti-ErbB2 humanized antibody trastuzumab, trastuzumab resistance emerges as a major and common clinical problem. Thus, circumventing trastuzumab resistance has become an urgent need. Recently, Src inhibitor saracatinib has drawn great attention for its key role in trastuzumab response. As shown in our previous study, H2-18, an anti-ErbB2 antibody, could potently induce programmed cell death (PCD) in trastuzumab-resistant breast cancer cells. Here we combined H2-18 and a Src inhibitor, saracatinib, and studied the antitumor activity of this drug combination in trastuzumab-resistant breast cancer cell lines. The results showed that H2-18 and saracatinib could synergistically inhibitmore »« less
https://doi.org/10.1016/J.BBRC.2016.09.111
In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells

Journal Article Shelton, Joseph W., E-mail: jwshelt@emory.edu ; Waxweiler, Timothy V. ; Landry, Jerome ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Poly(ADP-ribose) polymerase plays a critical role in the recognition and repair of DNA single-strand breaks and double-strand breaks (DSBs). ABT-888 is an orally available inhibitor of this enzyme. This study seeks to evaluate the use of ABT-888 combined with chemotherapy and radiation therapy (RT) in colorectal carcinoma models. Methods and Materials: RT clonogenic assays were performed on HCT116 and HT29 cells treated with 5-fluorouracil, irinotecan, or oxaliplatin with or without ABT. The surviving fraction at 2 Gy and dose-modifying factor at 10% survival were analyzed. Synergism was assessed by isobologram analysis for combination therapies. γH2AX and neutral comet assaysmore »« less
https://doi.org/10.1016/J.IJROBP.2013.02.015
Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53

Journal Article Romeo, Maria Anele ; Gilardini Montani, Maria Saveria ; Benedetti, Rossella ; ... - Experimental Cell Research

Colon cancer is one of the most common cancers, currently treated with traditional chemotherapies or alternative therapies. However, these treatments are still not enough effective and induce several side effects, so that the search of new therapeutic strategies is needed. The use of Poly-(ADP-ribose)-polymerase (PARP) inhibitors, although originally approved against BRCA-1 or BRCA-2 mutated cancers, has been extended, particularly in combination with other treatments, to cure cancers that do not display defects in DNA repair signaling pathways. The role of p53 oncosuppressor in the regulating the outcome of PARP inhibitor treatment remains an open issue. In this study, we addressedmore »« less
https://doi.org/10.1016/J.YEXCR.2021.112879
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies

Journal Article Oliveras-Ferraros, Cristina ; Vazquez-Martin, Alejandro ; Cufi, Silvia ; ... - Biochemical and Biophysical Research Communications

Highlights: {yields} Intrinsic trastuzumab resistance occurs in {approx}70% of metastatic HER2 + breast carcinomas (BC). {yields} Approximately 15% of early HER2 + BC relapse in spite of treatment with trastuzumab-based therapies. {yields} HER2-independent downstream pro-survival pathways might underlie trastuzumab refractoriness. {yields} Survivin is indispensable for proliferation and survival of HER2 + BC unresponsive to HER2-targeted therapies ab initio. {yields} Survivin antagonists may clinically circumvent the occurrence of de novo resistance to HER2-directed drugs. -- Abstract: Primary resistance of HER2 gene-amplified breast carcinomas (BC) to HER-targeted therapies can be explained in terms of overactive HER2-independent downstream pro-survival pathways. We here confirmmore »« less
https://doi.org/10.1016/J.BBRC.2011.03.039

Similar Records